Strategic fit Leverage Ablynx capabilities in Nanobody therapeutics to identify partnership opportunities with biotech firms or pharma companies seeking targeted biologics platforms, especially for inflammation, hematology, immuno-oncology and oncology programs.

Sanofi synergy Target potential collaborations that align with Sanofi’s interest in multi-specific Nanobody programs and M&A activity, highlighting co-development or in-licensing deals to accelerate late-stage candidates.

Global partnerships Explore licensing or co-development deals with Taisho Pharmaceutical and other regional players to expand commercial access, leveraging Ablynx’s Nanobody pipeline and Sanofi backing for cross-border market entry.

Data driven Position advanced protein engineering collaborations with AI/ML partners (e.g., LabGenius style) to optimize Nanobody discovery, offering joint R&D programs that shorten development timelines and reduce risk.

Diversified portfolio Identify opportunities around mRNA vaccine or infectious disease platforms by aligning with Translate Bio relationships, presenting combined capabilities in novel vaccine or therapeutic delivery leveraging Nanobody technology.